Insmed Accounts payable and other current liabilities (Note 11) decreased by 22.7% to $352.56M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 51.5%, from $232.67M to $352.56M. Over 4 years (FY 2021 to FY 2025), Accounts payable and other current liabilities (Note 11) shows an upward trend with a 38.2% CAGR.
An increase can signal improved cash management (extending payment terms) or higher operational activity, while a decrease may indicate faster payments to suppliers.
This represents short-term obligations to suppliers for goods and services received, along with other accrued expenses....
Standard metric for assessing working capital efficiency and trade credit usage across all industries.
current_liabilities_accounts_payable_and_accrued_liabili_26f6ce| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $125.03M | $182.12M | $214.99M | $285.21M | $232.67M | $305.02M | $409.84M | $456.06M | $352.56M |
| QoQ Change | — | +45.7% | +18.0% | +32.7% | -18.4% | +31.1% | +34.4% | +11.3% | -22.7% |
| YoY Change | — | +45.7% | +18.0% | +32.7% | — | — | — | +59.9% | +51.5% |